Celance (pergolide)-Important Safety Information from Lilly as approved by the Irish Medicines Board

Notice type: 3rd Party Publications

Date: 21/07/2008

Problem Or Issue:
Please find herewith an important safety communication from Eli Lilly informing of important safety information and changes to the prescribing information for celance/pergolide prompted by reports of fibrotic reactions, including valvulopathy, in chronic users of ergot-derived dopamine receptor agonists.

« Back